Camurus (CAMX.ST) Stock Price

Camurus Price

OMX·CLOSED
634.50SEK+12.50 (+1.99 %)
Market closed

Over the last 13 years Camurus grew revenue by 27.6% annually, reaching 2.27 B SEK. Earnings per share have grown at 19.3% per year over the last 11 years. For Camurus, the net margin of 32.5% is up versus -15.1% a few years ago. The consensus 12-month price target for Camurus is 795.60 SEK, about 25.4% above where the stock trades today. Of 15 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 45% above its 52-week low.

Camurus stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Camurus over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Camurus stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Camurus's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Camurus Stock Price History
DateCamurus Price
8/13/2026634.50 SEK
8/12/2026622.00 SEK
8/11/2026622.00 SEK
8/10/2026609.00 SEK
8/7/2026607.00 SEK
8/6/2026604.50 SEK
8/5/2026591.00 SEK
8/4/2026602.50 SEK
7/31/2026617.50 SEK
7/30/2026624.00 SEK
7/29/2026625.50 SEK
7/28/2026616.00 SEK
7/27/2026616.50 SEK
7/24/2026616.00 SEK
7/23/2026609.50 SEK
7/22/2026631.00 SEK
7/21/2026620.50 SEK
7/20/2026619.00 SEK
7/17/2026625.00 SEK
7/16/2026639.00 SEK
7/15/2026615.00 SEK
7/14/2026526.50 SEK
7/13/2026538.50 SEK
7/10/2026554.50 SEK
7/9/2026550.00 SEK
7/8/2026561.50 SEK
7/7/2026578.00 SEK
7/6/2026579.50 SEK
7/3/2026576.00 SEK
7/2/2026585.00 SEK
7/1/2026577.00 SEK
6/30/2026565.50 SEK
6/29/2026554.50 SEK
6/26/2026551.00 SEK
6/25/2026547.50 SEK
6/24/2026544.00 SEK
6/23/2026542.00 SEK
6/22/2026511.50 SEK
6/18/2026526.50 SEK
6/17/2026518.00 SEK
6/16/2026528.50 SEK
6/15/2026552.50 SEK
6/12/2026537.50 SEK
6/11/2026495.60 SEK
6/10/2026540.50 SEK
6/9/2026543.50 SEK
6/8/2026540.00 SEK
6/5/2026560.00 SEK
6/4/2026524.00 SEK
6/3/2026519.00 SEK
6/2/2026546.50 SEK
6/1/2026516.50 SEK
5/29/2026524.00 SEK
5/28/2026516.00 SEK
5/27/2026533.00 SEK
5/26/2026535.50 SEK
5/25/2026532.50 SEK
5/22/2026522.50 SEK
5/21/2026533.00 SEK
5/20/2026532.00 SEK
5/19/2026516.00 SEK
5/18/2026508.00 SEK
5/15/2026509.50 SEK
5/13/2026514.00 SEK
5/12/2026497.00 SEK
5/11/2026545.00 SEK
5/8/2026557.00 SEK
5/7/2026560.00 SEK
5/6/2026565.50 SEK
5/5/2026545.00 SEK
5/4/2026547.50 SEK
4/30/2026531.00 SEK
4/29/2026529.00 SEK
4/28/2026525.00 SEK
4/27/2026537.50 SEK
4/24/2026537.00 SEK
4/23/2026560.50 SEK
4/22/2026568.50 SEK
4/21/2026557.00 SEK
4/20/2026564.00 SEK
4/17/2026579.00 SEK
4/16/2026566.00 SEK
4/15/2026539.50 SEK
4/14/2026533.50 SEK
4/13/2026515.00 SEK
4/10/2026514.50 SEK
4/9/2026503.50 SEK
4/8/2026495.40 SEK
4/7/2026472.00 SEK
4/2/2026483.60 SEK
4/1/2026498.60 SEK
3/31/2026467.00 SEK
3/30/2026461.40 SEK
3/27/2026450.00 SEK
3/26/2026457.00 SEK
3/25/2026450.80 SEK
3/24/2026437.40 SEK
3/23/2026449.00 SEK
3/20/2026449.00 SEK
3/19/2026458.00 SEK
3/18/2026466.40 SEK
3/17/2026471.00 SEK
3/16/2026471.20 SEK
3/13/2026468.20 SEK
3/12/2026470.80 SEK
3/11/2026475.20 SEK
3/10/2026482.00 SEK
3/9/2026478.00 SEK
3/6/2026480.80 SEK
3/5/2026480.80 SEK
3/4/2026483.40 SEK
3/3/2026474.00 SEK
3/2/2026484.80 SEK
2/27/2026503.00 SEK
2/26/2026506.00 SEK
2/25/2026503.50 SEK
2/24/2026511.50 SEK
2/23/2026507.50 SEK
2/20/2026532.50 SEK
2/19/2026515.00 SEK
2/18/2026515.00 SEK
2/17/2026520.00 SEK
2/16/2026525.50 SEK
2/13/2026553.50 SEK
2/12/2026509.00 SEK
2/11/2026670.00 SEK
2/10/2026691.00 SEK
2/9/2026693.00 SEK
2/6/2026686.50 SEK
2/5/2026677.00 SEK
2/4/2026671.00 SEK
2/3/2026682.00 SEK
2/2/2026687.00 SEK
1/30/2026667.50 SEK
1/29/2026670.50 SEK
1/28/2026691.50 SEK
1/27/2026704.00 SEK
1/26/2026703.50 SEK
1/23/2026688.50 SEK
1/22/2026689.50 SEK
1/21/2026666.00 SEK
1/20/2026677.00 SEK
1/19/2026662.50 SEK
1/16/2026691.50 SEK
1/15/2026687.00 SEK
1/14/2026689.50 SEK
1/13/2026683.50 SEK
1/12/2026678.50 SEK
1/9/2026665.00 SEK
1/8/2026638.50 SEK
1/7/2026634.00 SEK
1/5/2026611.00 SEK
1/2/2026612.00 SEK
12/30/2025616.00 SEK
12/29/2025621.50 SEK
12/23/2025606.50 SEK
12/22/2025609.00 SEK
12/19/2025605.50 SEK
12/18/2025592.50 SEK
12/17/2025584.50 SEK
12/16/2025594.50 SEK
12/15/2025613.00 SEK
12/12/2025611.00 SEK
12/11/2025611.00 SEK
12/10/2025594.00 SEK
12/9/2025595.50 SEK
12/8/2025597.50 SEK
12/5/2025603.50 SEK
12/4/2025604.00 SEK
12/3/2025595.00 SEK
12/2/2025598.50 SEK
12/1/2025604.00 SEK
11/28/2025617.00 SEK
11/27/2025617.00 SEK
11/26/2025620.00 SEK
11/25/2025609.50 SEK
11/24/2025606.00 SEK
11/21/2025607.50 SEK
11/20/2025614.50 SEK
11/19/2025620.50 SEK
11/18/2025615.00 SEK
11/17/2025622.00 SEK
11/14/2025643.50 SEK
11/13/2025622.00 SEK
11/12/2025611.00 SEK
11/11/2025610.50 SEK
11/10/2025624.50 SEK
11/7/2025545.00 SEK
11/6/2025554.00 SEK
11/5/2025588.50 SEK
11/4/2025611.00 SEK
11/3/2025627.00 SEK
10/31/2025624.50 SEK
10/30/2025623.00 SEK
10/29/2025618.50 SEK
10/28/2025615.00 SEK
10/27/2025624.50 SEK
10/24/2025624.00 SEK
10/23/2025649.00 SEK
10/22/2025655.50 SEK
10/21/2025663.50 SEK
10/20/2025665.50 SEK
10/17/2025660.50 SEK
10/16/2025662.00 SEK
10/15/2025666.00 SEK
10/14/2025668.00 SEK
10/13/2025696.00 SEK
10/10/2025689.00 SEK
10/9/2025696.00 SEK
10/8/2025689.00 SEK
10/7/2025681.50 SEK
10/6/2025688.00 SEK
10/3/2025686.00 SEK
10/2/2025677.00 SEK
10/1/2025690.50 SEK
9/30/2025681.00 SEK
9/29/2025670.50 SEK
9/26/2025669.50 SEK
9/25/2025666.50 SEK
9/24/2025681.50 SEK
9/23/2025684.50 SEK
9/22/2025697.50 SEK
9/19/2025707.00 SEK
9/18/2025695.50 SEK
9/17/2025690.00 SEK
9/16/2025694.00 SEK
9/15/2025689.00 SEK
9/12/2025731.50 SEK
9/11/2025733.50 SEK
9/10/2025723.00 SEK
9/9/2025733.50 SEK
9/8/2025728.00 SEK
9/5/2025724.50 SEK
9/4/2025723.50 SEK
9/3/2025722.50 SEK
9/2/2025726.00 SEK
9/1/2025718.00 SEK
8/29/2025720.00 SEK
8/28/2025726.50 SEK
8/27/2025713.00 SEK
8/26/2025702.50 SEK
8/25/2025704.50 SEK
8/22/2025697.50 SEK
8/21/2025691.50 SEK
8/20/2025676.00 SEK
8/19/2025673.50 SEK
8/18/2025669.50 SEK
8/15/2025648.50 SEK
Access this data via the Eulerpool API
Get Free API Key

Camurus Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.72 B SEK
532.36 M SEK
431.44 M SEK
Jan 1, 2024
1.87 B SEK
469.17 M SEK
428.39 M SEK
Jan 1, 2025
2.27 B SEK
884.17 M SEK
735.57 M SEK
Jan 1, 2026 (e)
2.82 B SEK
508.34 M SEK
901.25 M SEK
Jan 1, 2027 (e)
3.76 B SEK
678.21 M SEK
1.41 B SEK
Jan 1, 2028 (e)
5.62 B SEK
1.01 B SEK
2.41 B SEK
Jan 1, 2029 (e)
7.79 B SEK
1.40 B SEK
3.04 B SEK
Jan 1, 2030 (e)
11.43 B SEK
2.06 B SEK
4.21 B SEK

Camurus Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 14, 2026, 1:50 PM
 
REVENUEB SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB SEK
EBITB SEK
EBIT MARGIN%
NET INCOMEB SEK
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.150.110.050.050.110.340.600.961.721.872.272.823.765.627.7911.43
-25.96-26.62-52.21-9.26114.29219.0579.1059.3379.508.8021.3224.4233.4349.3638.6646.73
100.0098.2396.3085.7178.1089.5585.8389.2392.8993.0993.1193.1193.1193.1193.1193.11
0.150.110.050.040.080.300.520.851.591.742.112.623.505.237.2510.64
-0.20-0.10-0.24-0.29-0.36-0.21-0.110.070.530.470.880.510.681.011.402.06
-132.47-90.27-450.00-585.71-342.86-61.19-18.677.4331.0025.1239.0318.0318.0318.0218.0318.03
-0.16-0.08-0.19-0.23-0.29-0.17-0.090.060.430.430.740.901.412.413.044.21
-431.25-49.69137.5023.1623.50-42.21-46.11-161.11683.64-0.7071.7322.5956.6070.4526.4038.45
40.7241.1641.8846.7253.5655.6456.7257.5555.5659.9360.3160.3160.3160.3160.3160.31
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Camurus generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Camurus retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Camurus's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Camurus has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Camurus's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Camurus stock margins

The Camurus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Camurus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Camurus.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
85.79 %
-18.71 %
-15.06 %
Jan 1, 2022
89.20 %
7.52 %
5.81 %
Jan 1, 2023
92.87 %
31.01 %
25.13 %
Jan 1, 2024
93.07 %
25.12 %
22.94 %
Jan 1, 2025
93.11 %
39.03 %
32.47 %
Jan 1, 2026 (e)
93.11 %
18.03 %
31.97 %
Jan 1, 2027 (e)
93.11 %
18.03 %
37.53 %
Jan 1, 2028 (e)
93.11 %
18.03 %
42.83 %

Camurus Stock Revenue, EBIT, Earnings per Share

The Camurus earnings per share therefore indicates how much revenue Camurus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
10.59 SEK
-1.98 SEK
-1.59 SEK
Jan 1, 2022
16.62 SEK
1.25 SEK
0.97 SEK
Jan 1, 2023
30.90 SEK
9.58 SEK
7.77 SEK
Jan 1, 2024
31.17 SEK
7.83 SEK
7.15 SEK
Jan 1, 2025
37.56 SEK
14.66 SEK
12.20 SEK
Jan 1, 2026 (e)
47.59 SEK
8.43 SEK
15.22 SEK
Jan 1, 2027 (e)
63.49 SEK
11.25 SEK
23.83 SEK
Jan 1, 2028 (e)
94.81 SEK
16.79 SEK
40.61 SEK

Camurus business model & stock analysis

Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions.

Camurus SWOT Analysis

Strengths

Camurus AB possesses a strong portfolio of innovative pharmaceutical products.

The company has a well-established reputation in the industry and is trusted by healthcare professionals.

Camurus AB has a robust and efficient manufacturing process, resulting in high-quality products.

The company's strong financial position allows for investments in research and development.

Weaknesses

Camurus AB may face challenges in terms of market competition and patent protection for its products.

The company's reliance on a limited number of key customers may pose a risk to its revenue stream.

Camurus AB's geographic presence is primarily focused on specific regions, limiting its market reach.

The company's dependence on external suppliers for raw materials may result in potential supply chain disruptions.

Opportunities

The growing demand for innovative pharmaceutical solutions presents opportunities for Camurus AB to expand its market share.

Strategic partnerships and collaborations with other pharmaceutical companies can enhance Camurus AB's product development capabilities.

Expansion into new geographic markets can provide Camurus AB with access to untapped customer segments.

The increasing focus on personalized medicine opens avenues for the development of tailored pharmaceutical products.

Threats

Regulatory changes and stringent approval processes may delay or hinder the launch of new products by Camurus AB.

The presence of generic competitors in the pharmaceutical market poses a threat to Camurus AB's market share and pricing strategy.

Rapid advancements in technology may require significant investments to keep up with industry trends.

Economic fluctuations and healthcare budget constraints can impact the purchasing power of Camurus AB's target customers.

Camurus Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Camurus historical P/E ratio, EBIT multiple, and P/S ratio

Camurus annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Camurus shares outstanding

The number of shares of Camurus was 60.31 M in 2025. This indicates how many shares Camurus is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
56.72 M Stocks
Jan 1, 2022
57.55 M Stocks
Jan 1, 2023
55.56 M Stocks
Jan 1, 2024
59.93 M Stocks
Jan 1, 2025
60.31 M Stocks
Jan 1, 2026 (e)
60.31 M Stocks
Jan 1, 2027 (e)
60.31 M Stocks
Jan 1, 2028 (e)
60.31 M Stocks

Current Camurus forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
3.58 %
Buy
86.67 % (13)
Hold
13.33 % (2)
Sell
0.00 % (0)
12M Price Target
795.60
Last Price
634.50
Currency
SEK
12M Return Potential
25.39 %
LTM Return
0 %

Camurus Earnings Calls

2025

Camurus Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/8/20241.97SEK-418.40 MSEK-2024 Q1
2/12/20240.93SEK-379.73 MSEK-2023 Q4
7/13/20230.69SEK--SEK-2023 Q2
5/10/20233.01SEK-292.02 MSEK-2023 Q1
2/14/20231.82SEK-341.51 MSEK-2022 Q4
11/10/20220.14SEK-248.72 MSEK-2022 Q3
7/15/2022-0.25SEK-225.41 MSEK-2022 Q2
5/12/2022-0.27SEK-205.03 MSEK-2022 Q1
2/16/2022-0.33SEK-179.65 MSEK-2021 Q4
7/15/2021-0.53SEK-144.13 MSEK-2021 Q2

EESG©

Eulerpool ESG Scorecard© for the Camurus stock

89/100
99
Environment
99
Social
69
Governance
E

Environment

20
Scope 1 - Direct Emissions159
Scope 2 - Indirect emissions from purchased energy12
Scope 3 - Indirect emissions within the value chain386
Total CO₂ emissions171
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees67
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Camurus shareholder structure

% Name
3.87954%
Swedbank Robur Fonder AB
Swedbank Robur Fonder AB
2.20151%
Carnegie Fonder AB
Carnegie Fonder AB
2.07354%
Capital World Investors
Capital World Investors
1.33494%
Lansförsäkringar Fondförvaltning AB
Lansförsäkringar Fondförvaltning AB
1.22221%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.99912%
Devon Equity Management Ltd.
Devon Equity Management Ltd.
...

Camurus Beneficial Ownership Filings (SEC 13D/G)

Free Float
64.8%
Float Shares
-
Shares Outstanding
-

Camurus Executives and Management Board

19 members · avg. age 60 · 37 % women

FT

Mr. Fredrik Tiberg (62)

Chief Executive Officer, Chief Scientific Officer, Director · since 2002

36.63 M SEK

Management

BS

Ms. Behshad Sheldon (62)

President · since 2018

350,000.00 SEK
AV

Mr. Anders Vadsholt

Chief Financial Officer

–
MJ

Mr. Markus Johnsson (53)

Senior Vice President R and D

–
TM

Mr. Torsten Malmstroem (57)

Chief Technical Officer · since 2019

–
BT

Mr. Bo Tarras-Wahlberg (50)

Vice President, General Counsel

–
AM

Ms. Annette Mattsson (59)

Vice President - Regulatory Affairs

–

Board of Directors

PW

Mr. Per Wallstroem (75)

Independent Chairman of the Board

825,000.00 SEK
EJ

Ms. Erika Johnsson (55)

Independent Director

485,000.00 SEK
SP

Mr. Stefan Persson (58)

Director

405,000.00 SEK
HH

Ms. Hege Hellstroem (60)

Independent Director

405,000.00 SEK
JL

Mr. Jakob Lindberg (53)

Independent Director

385,000.00 SEK
EB

Dr. Elisabeth Bjork (64)

Independent Director

–

Frequently asked questions about Camurus

Camurus AB represents a set of values and corporate philosophy rooted in innovation, collaboration, and patient-centricity. As a pharmaceutical company, Camurus AB is committed to developing and commercializing innovative drug delivery solutions to improve the lives of patients. They value scientific excellence, and their corporate philosophy emphasizes the importance of integrity, transparency, and ethical behavior in all aspects of their operations. Camurus AB strives to foster partnerships with healthcare professionals, patients, and stakeholders to deliver impactful treatments and make a positive difference in the field of medicine.

The business model of Camurus AB is focused on the development and commercialization of innovative pharmaceutical products. Camurus specializes in long-acting medications, utilizing their proprietary FluidCrystal® technology to create advanced drug delivery systems. These systems enhance the efficacy, safety, and convenience of medication administration. The company primarily operates in the field of severe and chronic conditions, particularly within pain management and addiction treatment. By leveraging their expertise in drug formulation and delivery, Camurus aims to improve patient outcomes and quality of life.

Camurus AB is primarily active in the pharmaceutical industry.

The main competitors of Camurus AB in the market are pharmaceutical companies such as Indivior PLC, Titan Pharmaceuticals Inc., and DURECT Corporation.

Camurus AB is a Swedish pharmaceutical company specializing in developing and commercializing innovative drug delivery systems. Founded in 1991, Camurus has built a strong reputation for its proprietary drug delivery technologies, including the FluidCrystal® and the Buvidal® depot products. The company has successfully delivered numerous products to market, primarily in the areas of pain management and opioid dependence. With a focus on providing effective and patient-friendly medications, Camurus AB continues to expand its product portfolio and collaborate with global partners. This steadfast commitment to innovation has established Camurus AB as a leader in the pharmaceutical industry.

Some significant milestones achieved by Camurus AB include the approval and launch of their opioid dependence treatment medication, Buvidal® (buprenorphine and naloxone extended-release solution), in several countries, including the United States and European Union. The company has also received regulatory approvals for their product pipeline, such as the long-acting CAM2038 for the treatment of opioid addiction and pain, which further strengthens their position in the pharmaceutical market. Additionally, Camurus AB has formed strategic partnerships and collaborations with various pharmaceutical companies to commercialize their products globally. These milestones highlight the company's commitment to innovation and healthcare advancements in the treatment of addiction and pain management.

Camurus AB is primarily present in several countries and regions. The company has a strong presence in Europe, with a focus on Scandinavia. It operates in Sweden, where it is headquartered, as well as in Norway, Denmark, and Finland. Additionally, Camurus AB has expanded its operations to other European countries, including the United Kingdom, Germany, France, and Spain. It aims to further expand its global footprint through strategic partnerships and collaborations.

Analysts currently set an average price target of 790.50 SEK for the Camurus stock (median: 795.60 SEK), implying +24.6 % versus the latest price. The consensus is based on 15 analyst ratings.

Camurus Analyst Price Targets 2026

15 analysts currently rate the Camurus stock: 13 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Camurus to generate revenue of 2.82 B SEK and earnings per share of 14.94 SEK.

Camurus Analyst Price Targets 2026

Converted at the current exchange rate, the Camurus share trades at 57.54 EUR (634.50 SEK).

The Camurus share (CAMX.ST) is listed on 7 stock exchanges, including: Frankfurt (7CA.F), Düsseldorf (7CA.DU), London (0RD1.L), London (0RD1.L).

Camurus AB is a Swedish biopharmaceutical company specializing in the development of innovative drugs. The company was founded in 1991 and is headquartered in Lund. Camurus has unique expertise in the formulation and manufacturing of long-acting drugs and is a leader in the development and commercialization of products for pain treatment, addiction disorders, and oncology. Camurus employs over 200 employees worldwide and pursues an international growth strategy with a focus on North America and Europe. The company collaborates closely with research-based pharmaceutical companies and academic institutions to help innovative drugs break through. Camurus is a strong and strategically focused company with a high degree of flexibility, dynamism, and innovation spirit. Camurus has two main divisions: the "Pharmaceuticals" business unit and the "Biovive" business unit. The "Pharmaceuticals" business unit focuses on the discovery and development of long-acting drugs in various therapeutic areas such as pain, addiction disorders, and oncology. The "Biovive" business unit is dedicated to the development of clinical dietary supplements and diagnostics to support oncology patient care. Camurus' flagship product is the opioid substitution preparation "Bunavail," which is used to treat opioid dependency. The uniqueness of Bunavail is that it is applied as a film on the inner cheek, ensuring a slow and continuous release of the active ingredient. This achieves better therapeutic effectiveness while reducing the potential for abuse. Camurus has other products in the pipeline, such as the pain product "CAM2038," which is intended for long-term therapy in chronic and acute pain. Camurus has successfully partnered with major pharmaceutical companies such as Braeburn Pharmaceuticals, ICM Pharma, and Meda to distribute its products worldwide. Camurus is also able to market its own products that are registered in the US, Europe, and other key markets. The company has international offices in the US and Europe and is continuously working to expand its network to increase global presence and growth. In summary, Camurus is an innovative biopharmaceutical company that focuses on the development of long-acting drugs in various therapeutic areas. Camurus' unique technology provides patients with better therapeutic effectiveness and safe drug handling, contributing to a better quality of life for patients. Camurus has a clear growth strategy to strengthen its position as a leading provider in the industry.

The expected revenue of Camurus is 2.82 B SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Camurus is 901.25 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Camurus is currently 42.46. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Camurus stock.

The price-to-sales ratio (P/S) of Camurus is currently 13.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Camurus stock.

The Eulerpool Quality Score for Camurus is 7/10.

The ISIN of Camurus is SE0007692850. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Camurus is A2ABG7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Camurus is CAMX.ST. The ticker symbol is used to trade Camurus shares on the stock exchange.

Camurus paid dividends every year for the past 0 years.

Camurus is assigned to the 'Health' sector.

The dividends of Camurus are distributed in SEK.

All fundamentals and in-depth analysis of Camurus

Our stock analysis for Camurus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Camurus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Camurus Stock
Camurus Revenue→
Camurus Stock
Camurus Net Income→
Camurus Stock
Camurus P/E→
Camurus Stock
Camurus P/S→
Camurus Stock
Camurus EBIT→
Camurus Stock
Camurus Dividend→
Camurus Stock
Camurus Directors Dealings→
Camurus Stock
Camurus Stocks→
Camurus Stock
Camurus Market capitalization→
Camurus Stock
Camurus Debt→
Camurus Stock
Camurus Liabilities→
Camurus Stock
Camurus Equity→
Camurus Stock
Camurus AAQS→
Camurus Stock
Camurus Employees→
Camurus Stock
Camurus ROE→
Camurus Stock
Camurus ROA→
Camurus Stock
Camurus ROCE→
Camurus Stock
Camurus News→
Camurus Stock
Camurus Analyst Price Targets→

Health Stocks

CanadaBis CapitalCAMP4 TherapeuticsCanBas CoCambridge Nutritional SciencesCANbridge PharmaceuticalsCambridge Cognition HoldingsCandel TherapeuticsCambium BioCann GroupCaliway Biopharmaceuticals CoCannabis Global,Calithera BiosciencesAll Stocks A–Z →